ReviewSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026
Phytochemicals with potential NMDAR-inhibitory activities: a review of neuroprotective mechanisms against excitotoxicity.
Review in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The N-methyl-D-aspartate receptors (NMDARs) are ionotropic glutamate receptors in the central nervous system (CNS) that play a crucial role in synaptic plasticity, learning, and memory. However, NMDAR overstimulation is a critical pathological feature in neurodegenerative diseases, stroke, epilepsy, and traumatic brain injury. This excitotoxic cascade triggers massive intracellular calcium influx, oxidative stress, and mitochondrial dysfunction, ultimately driving neuronal apoptosis. In this regard, phytochemicals have emerged as safe, multitargeting NMDAR inhibitors with significant therapeutic potential. This review synthesizes current experimental evidence regarding the neuroprotective potential of major phytochemical classes, including glycosides (e.g., vitexin, ginsenosides), polyphenols (e.g., quercetin, resveratrol), alkaloids (e.g., cytisine, huperzine A), and terpenoids (e.g., bilobalide, fucoxanthin). The results of these studies demonstrate that these bioactive compounds mitigate excitotoxicity via multiple mechanisms, including direct receptor blockade, inhibiting specific subunits (such as GluN2B), and downregulating NMDAR expression. Furthermore, they restore neuronal homeostasis by modulating downstream signaling pathways; thereby suppressing neuroinflammation and apoptosis. It can be concluded that phytochemicals represent a vital reservoir of modulatory agents that protect against glutamate-induced neurotoxicity. Hence, they offer a compelling framework for future drug discovery in CNS therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.